What is SHPH's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.03B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for SHPH?

P/E (TTM) is n/a and 52-week range is $2.58 to $55.90 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s SHPH figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for SHPH?

The company profile lists net income (TTM) near $-18M, EPS (TTM) near $-27.52 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Shuttle Pharmaceuticals Holdings Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Gaithersburg, Maryland, US, 640K shares outstanding, ISIN US8256934014 when available from company profile and filing metadata.

Shuttle Pharmaceuticals Holdings Inc

$SHPH

Health Care · Biotechnology

IR Run Scenarios

$5.33

-3.96%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Shuttle Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company, which engages in the development of novel therapies for cancer. The company is headquartered in Gaithersburg, Maryland and currently employs 2 full-time employees. The company went IPO on 2022-08-31. Its product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer-oriented diagnostics assets: PC-RAD Test, a blood test to predict clinical response to radiation therapy and PSMA-B ligand for potential use as a theranostic agent. Ropidoxuridine (IPdR) is for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. SP-1-161 is a candidate lead of compounds demonstrating activation of the ATM gene product (mutated in Ataxia-Telangiectasia). SP-2-225 is a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. SP-1-303 is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.

Employees

Website

shuttlepharma.com/

IPO

2022-08-31

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)